Rocket Pharmaceuticals (RCKT) Tops Q3 EPS by 4c

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q3 EPS of ($0.71), $0.04 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Rocket Pharmaceuticals (RCKT) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• AMETEK secures $7.5 billion in credit facilities for Indicor acquisition
• Schwab's May activity shows margin loans nearly double